Evercore ISI Starts Caris Life Sciences Inc (CAI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Evercore ISI Starts Caris Life Sciences Inc (CAI) at Outperform
July 14, 2025 6:07 AM EDT
Wolfe Research analyst Doug Schenkel initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Outperform rating and a price target of $32.00.
The analyst comments "INITIATE OUTPERFORM with a $32 PT (~10x and ~30x our 2026E sales and 2027E EBITDA estimates, respectively) CAI is positioned to (1)... More
July 14, 2025 5:45 AM EDT
Nephron analyst Sasha Simpson initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $33.00.
For an analyst ratings summary and ratings history on Caris Life Sciences Inc... More
July 14, 2025 5:32 AM EDT
TD Cowen analyst Dan Brennan initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $32.00.
The analyst comments "We initiate at Buy, $32 PT. Even after the stock's strong early performance we see an attractive... More
July 14, 2025 5:32 AM EDT
Citi analyst Patrick Donnelly initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $34.00.
The analyst comments "We are initiating coverage of Caris Life Sciences with a Buy/HR rating and a target price... More
July 14, 2025 2:13 AM EDT
JPMorgan analyst Rachel Vatnsdal initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Overweight rating and a price target of $31.00.
The analyst comments: "CAI is a leading diagnostics (Dx) company focused on enabling precision medicine via its platform that captures comprehensive molecular... More
July 14, 2025 1:08 AM EDT
Guggenheim analyst Subbu Nambi initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $32.00.
The analyst comments: "We are initiating coverage of Caris Life Sciences, Inc. (CAI) with a BUY rating and a price target... More
July 14, 2025 12:41 AM EDT
BTIG analyst Mark Massaro initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $38.00.
The analyst comments: "We initiate coverage of Caris Life Sciences with a Buy rating and $38 PT. Caris is a rapidly-growing market... More
July 13, 2025 10:56 AM EDT
BofA Securities analyst Michael Ryskin initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $31.00.
The analyst comments: "Caris Life Sciences (CAI) is a molecular diagnostic company with a differentiated, data-driven platform for tissue-based tumor profiling.... More
